Skip to main content

Table 1 Baseline characteristics of patients

From: Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial

CharacteristicAmantadinePlaceboTotalP-value
(N = 16)(N = 17)(N = 33) 
Age, mean ± SD, years50.69 ± 10.1854.67 ± 9.6352.79 ± 9.940.154
Female, N (%)12 (75)8 (47.1)21 
> 1 year of college, N (%)14 (87.5)15 (88.2)29 
Recurrent major depression10 (62.5)10 (58.8)20 
Bipolar depression, N (%)
 Bipolar I3 (18.75)4 (23.5)7 
 Bipolar II3 (18.75)3 (17.6)6 
Mean number of depressive episodes per year (past 3 years prior to current episode)1.0 ± 1.11.04 ± 1.21.02 ± 1.10.904
Mean duration of depressive episodes (weeks) (past 3 years prior to current episode)25.6 ± 2123.7 ± 1824.6 ± 190.781
Duration of illness (years)12.4 ± 917.6 ± 1115.1 ± 100.135
Patients with antidepressant or mood stabilizing co-medication, N (%)12 (75)8 (47.1)20 
Amitriptyline336 
Doxepin112 
Mirtazapine1 1 
Clomipramine1 1 
Trimipramine1 1 
Tranylcypromine1 1 
Moclobemide1 1 
Sertraline 22 
Paroxetine112 
Dibenzepine1 1 
Maprotiline 11 
Lithium224 
Carbamazepine224 
Valproate1 1 
Lorazepam314 
Alprazolam1 1 
Zolpidem 11 
Sulpirid1 1 
L-Thyroxin 22 
Dihydroergotamine1 1 
Estrogenes112